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Objective. To investigate the pharmacokinetics,
effectiveness, and safety of subcutaneous (SC) abatacept
treatment over 24 months in patients with polyarticular-
course juvenile idiopathic arthritis (JIA).
Methods. In this phase III, open-label, interna-
tional, multicenter, single-arm study, patients with poly-
articular JIA (cohort 1, ages 6–17 years and cohort 2, ages
2–5 years) in whom treatment with ≥1 disease-modifying
antirheumatic drug was unsuccessful received weight-tiered
SC abatacept weekly: 10 to <25 kg (50 mg), 25 to <50 kg
(87.5 mg), ≥50 kg (125 mg). Patients who had met the JIA–
American College of Rheumatology 30% improvement cri-
teria (achieved a JIA-ACR 30 response) at month 4 were
given the option to continue SC abatacept to month 24.
ClinicalTrials.gov identifier: NCT01844518.
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The primary end point was the abatacept steady-state
serum trough concentration (Cminss) in cohort 1 at month
4. Other outcome measures included JIA-ACR 30, 50, 70,
90, 100, and inactive disease status, the median Juvenile
Arthritis Disease Activity Score in 71 joints using the C-
reactive protein level (JADAS-71–CRP) over time, safety,
and immunogenicity.
Results. The median abatacept Cminss at month 4
(primary end point) and at month 24 was above the tar-
get therapeutic exposure (10 lg/ml) in both cohorts. The
percentage of patients who had achieved JIA-ACR 30, 50,
70, 90, or 100 responses or had inactive disease responses
at month 4 (intent-to-treat population) was 83.2%, 72.8%,
52.6%, 28.3%, 14.5%, and 30.1%, respectively, in cohort 1
(n = 173) and 89.1%, 84.8%, 73.9%, 58.7%, 41.3%, and
50.0%, respectively, in cohort 2 (n = 46); the responses
were maintained to month 24. The median (interquartile
range) JADAS-71–CRP improved from baseline to month
4: cohort 1, from 21.0 (13.5, 30.3) to 4.6 (2.1, 9.4); cohort
2, from 18.1 (14.0, 23.1) to 2.1 (0.3, 4.4). Improvements
were sustained to month 24, at which time 27 of 173
patients (cohort 1) and 11 of 22 patients (cohort 2) had
achieved JADAS-71–CRP remission. No unexpected
adverse events were reported; 4 of 172 patients (2.3%) in
cohort 1 and 4 of 46 (8.7%) in cohort 2 developed anti-
abatacept antibodies, with no clinical effects.
Conclusion. Weight-stratified SC abatacept yielded
target therapeutic exposures across age and weight groups,
was well tolerated, and improved polyarticular JIA symp-
toms over 24 months.
Juvenile idiopathic arthritis (JIA) is a rheumatic
disease presenting in children <16 years of age (1–3). For
polyarticular-course JIA (JIA of any category with ≥5 af-
fected joints [1,4,5]), methotrexate (MTX) is the recom-
mended first-line disease-modifying antirheumatic drug
(DMARD) therapy (3). If disease activity remains moder-
ate or high after 3 months of MTX treatment, a biologic
agent is frequently initiated and a tumor necrosis factor
inhibitor (TNFi) is most commonly employed, followed
by an anti–interleukin-6 agent or abatacept (6). However,
it is important to have multiple treatment options in this
pediatric population, particularly for patients who are
intolerant of or do not respond to MTX or TNFi (2,7–15)
or who live in a tuberculosis-endemic country.
Abatacept, which selectively modulates the CD80/
CD86:CD28 costimulatory signal required for full T cell
activation, has a distinct mechanism of action upstream of
that of other currently available treatments for rheumatic
diseases (13,16–18). In adults with rheumatoid arthritis
(RA), intravenous (IV) abatacept inhibits structural dam-
age, reduces disease progression, and improves function
and health-related quality of life, with good safety and tol-
erability (16,19,20). IV-administered abatacept has been
proven effective and well tolerated in polyarticular JIA
clinical trials and real-world settings (21), with benefits of
treatment sustained up to 7 years in patients ages 6–17
years (2,9,13). A subcutaneous (SC) abatacept formula-
tion is also available, allowing for administration at home,
thus providing greater flexibility (22).
The exposure–response relationship established in
RA and JIA has demonstrated that abatacept steady-state
serum trough concentration (Cminss) is a good predictor of
efficacy (23,24). A Cminss of 10 lg/ml has been shown to
correlate with near-maximal efficacy, based on response
as assessed by the Disease Activity Score in 28 joints (24)
in RA and the JIA–American College of Rheumatology
30% improvement criteria (JIA-ACR 30) (21,23,25) in
JIA. In adults with RA, a weight-tiered 10 mg/kg monthly
IV dose and 125 mg weekly SC fixed dose of abatacept
have shown equivalent efficacy and comparable safety
(22), but the effectiveness and safety of SC abatacept in
polyarticular JIA have yet to be demonstrated in a clinical
trial.
The aim of this study was to investigate the phar-
macokinetics (PK), effectiveness, safety, and immuno-
genicity of weekly weight-tiered treatment with SC
abatacept in patients with active polyarticular JIA, includ-
ing those ≥2 years of age, over a period of 24 months.
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PATIENTS AND METHODS
Study design. This 24-month, single-arm, open-label,
international, multicenter, 2-part, phase III study (26) was initi-
ated in August 2013 and conducted across 48 centers worldwide
by members of the Paediatric Rheumatology International Trials
Organisation (PRINTO) (27) and the Pediatric Rheumatology
Collaborative Study Group (PRCSG) (see Appendix A for inves-
tigators who participated in this study). The study included 2 age
cohorts (cohort 1, ages 6–17 years and cohort 2, ages 2–5 years).
During the first 4 months (part 1), patients received open-label
SC abatacept weekly, based on body-weight tier at each study
visit (10 to <25 kg [50 mg], 25 to <50 kg [87.5 mg], and ≥50 kg
[125 mg]) (see Supplementary Materials, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.
1002/art.40466/abstract for rationale for the dosing regimen).
At month 4, JIA-ACR 30 responders (28) were given the
opportunity to participate in a 20-month extension (part 2 of the
study) and continue open-label abatacept treatment according to
the previous dosing regimen; part 1 and part 2 formed the 24-
month cumulative period. Also at month 4, JIA-ACR 30 nonre-
sponders were given the option to continue SC abatacept for an
additional 3 months and to discontinue treatment if a JIA-ACR
30 response was not achieved by month 7. After part 2, long-term
follow-up began, in which patients who completed both parts of
the study entered a post-study drug access program. The study
was conducted in accordance with the Declaration of Helsinki
(29), the International Conference on Harmonisation Guidelines
for Good Clinical Practice, and local regulations. At each site, an
institutional review board or independent ethics committee
approved the protocol, consent forms, and any other written
information provided to patients or their legal representatives.
Patients. Enrolled patients met the International
League of Associations for Rheumatology criteria for JIA (4) in
1 of the following categories: extended oligoarticular JIA, poly-
articular JIA rheumatoid factor (RF) positive, polyarticular JIA
RF negative, enthesitis-related arthritis, psoriatic arthritis, or
systemic JIA (with systemic features absent for ≥6 months prior
to enrollment). Patients also had a history of ≥5 joints with active
disease and active articular disease at baseline, defined as ≥2
active joints and ≥2 joints with limitation of motion.
In addition, patients were naive to treatment with aba-
tacept but may have had an inadequate response or prior intoler-
ance to ≥1 nonbiologic or biologic DMARD, including TNFi.
Patients with systemic JIA at onset were restricted to ≤10% of
the study population, and those with a prior inadequate response
to TNFi or other biologic DMARDs were restricted to ≤30% of
the study population (see Supplementary Materials, available
at http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract).
All patients or their legal representatives provided written
informed consent prior to study entry.
Study end points. The primary end point was abatacept
Cminss in cohort 1 (ages 6–17 years) at month 4 of the study (end
of part 1). Secondary end points included the proportion of
patients in cohort 1 achieving JIA-ACR 30 response by the end
of part 1 and the proportion of patients with serious adverse
events (SAEs), AEs, AEs leading to discontinuation, death,
marked laboratory abnormalities, and positive immunogenic
responses (defined as the presence of antibodies reactive with
abatacept in serum) (30) in both cohorts over parts 1 and 2.
Abatacept Cminss to month 24 (end of part 2) was an exploratory
end point for both cohorts.
Prespecified exploratory efficacy end points for both
cohorts included the proportions of patients achieving JIA-ACR
30, 50, 70, 90, 100 responses or inactive disease (modified criter-
ia), defined as absence of active joints, physician’s global assess-
ment of disease severity ≤10 mm, and C-reactive protein (CRP)
level ≤0.6 mg/dl (based on the normal range for CRP as defined
by the central analysis site) (31) over time to the end of part 2.
JIA-ACR response rates were not corrected for MTX or
corticosteroid use; however, if patients received an intraarticular
corticosteroid injection, the treated joint was designated as active
for the following 3 months. Other prespecified exploratory end
points for cohort 1 included median post-baseline values of the 6
JIA-ACR core set variables: number of active joints, number of
joints with limitation of motion, physician’s global assessment,
parent’s global assessment of patient overall well-being, cross-
culturally adapted and validated version of the Childhood Health
Assessment Questionnaire disability index (C-HAQ DI) (32),
and laboratory marker of acute inflammation (CRP level).
Post hoc analyses in both cohorts were conducted to determine
the median Juvenile Arthritis Disease Activity Score in 71
joints using the CRP level (JADAS-71–CRP) (33,34) over time,
and the proportion of patients achieving low disease activity
according to the JADAS-71–CRP (cutoff value in polyarthritis
≤3.8) and remission (defined as a JADAS-71–CRP value of ≤1
for ≥6 months) (33,35). In addition, post hoc subgroup analyses
of JIA-ACR response rates and proportions of patients achieving
JADAS-71–CRP low disease activity and remission in cohort 1
were performed using baseline concomitant MTX treatment,
prior biologic treatment, and JIA category as subgroups (see
Supplementary Materials, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40466/abstract).
Analysis populations. In both cohorts, the PK analysis
population for month 4 (end of part 1) comprised treated pa-
tients for whom PK measurements were collected in the 4–10-
day window after the most recent SC dose; these patients also
had 7 consecutive weekly SC abatacept injections at the same
dosage prior to month 4. The PK analysis population at the time
points other than month 4 also comprised those patients with
PK measurements collected in the 4–10-day window after the
most recent SC dose.
Effectiveness analyses were conducted on the intent-to-
treat (ITT) population (defined as all treated patients) for both
cohorts in part 1, as prespecified. For part 2, an “as-observed”
analysis was planned for both cohorts. However, in cohort 1
(ages 6–17 years), ITTanalyses were also performed for the eval-
uation of effectiveness (sensitivity analysis), except for median
post-baseline values for JADAS-71–CRP and the 6 JIA-ACR
core set variables over the cumulative period. In cohort 2 (ages
2–5 years), only as-observed analyses were performed for part 2,
as not all patients had completed treatment at the time of data-
base locking.
Safety analyses were performed on the ITT population in
both cohorts, taking into consideration all events during parts 1
and 2. Marked laboratory abnormalities criteria were prespecified
(see Supplementary Materials, available at http://onlinelibrary.
wiley.com/doi/10.1002/art.40466/abstract). Immunogenicity was as-
sessed in patients in the ITT population for whom ≥1 post-base-
line immunogenicity result was collected.
Statistical analysis, sample size, and power calculation.
As the aim of this study was to assess the PK of SC abatacept
treatment, it was not powered for statistical hypothesis testing. A
sample size of ~160 patients for cohort 1 (ages 6–17 years) was
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planned to allow for assessment of PK, effectiveness, safety, and
immunogenicity, resembling the sample size of the 4-month
lead-in phase of the IVabatacept JIA study (13). Enrollment of
~160 patients into the 3 body-weight tiers was predicted to
ensure that the half-width of the 90% confidence interval (90%
CI) for Cminss would be within 18% of the true population mean
for each body-weight tier group, calculated based on a log-trans-
formed standard deviation for Cminss of 0.49. For JIA-ACR 30
response, a sample of 160 patients would yield a precision of
7.4% for the half-width of the 95% CI, assuming an underlying
true responder rate of 64%, as seen with IV abatacept in JIA
(13). For cohort 2 (ages 2–5 years), a sample size of ≥30 patients
permitted initial descriptive assessment of PK, effectiveness,
safety, and immunogenicity.
All effectiveness, safety, and PK analyses were descrip-
tive, with no formal statistical testing. For effectiveness analyses
using the ITT population, patients with missing data were
imputed as nonresponders. CIs for proportions were computed
using normal approximation, provided that the actual number of
events was ≥5; otherwise, computed CIs were calculated using
an exact method. In order to investigate the impact of immuno-
genicity on effectiveness, safety, and PK, a clinical review of the
data on effectiveness, safety, and PK for patients who had posi-
tive immunogenic responses was performed.
RESULTS
Patient disposition and baseline characteristics. A
total of 219 patients entered part 1 of the study; 173 were
ages 6–17 years (cohort 1) and 46 were ages 2–5 years (co-
hort 2). As shown in Figure 1, 132 patients (76.3%) in
cohort 1 and 24 (52.2%) in cohort 2 completed both parts
1 and 2. In both cohorts, the discontinuation rate was low
across both parts of the trial; overall, the main reasons
for discontinuation were lack of efficacy, withdrawal of
consent, and AEs. Treatment in the cumulative period was
ongoing for 15 patients (32.6%) in cohort 2 at the time of
database locking. Baseline demographic and disease char-
acteristics for cohorts 1 and 2 are shown in Table 1.
Whereas 41.0% of patients (71 of 173) in cohort 1 had a
disease duration of ≥2 years, most patients (91.3% [42 of
46]) in cohort 2—which included patients as young as 2
years of age—had a disease duration of <2 years (median
0.5 years). At baseline, 78.6% of patients in cohort 1 and
80.4% in cohort 2 were receiving concomitant MTX. A
protocol violation occurred in cohort 1, due to inclusion of
5 patients from noneligible JIA categories in the analysis.
The median exposure to abatacept during the cumulative
period was 24.3 months (range 1.9–28.0) in cohort 1 and
24.1 months (range 4.0–26.2) in cohort 2.
Pharmacokinetics. The median abatacept Cminss
values at months 4 and 24 in cohort 1 were 40.5 lg/ml
(range 9.3–97.0; n = 135) and 43.0 lg/ml (range 0.0–105.2;
n = 79), respectively, and were 51.2 (20.1–122.1; n = 30)
and 58.7 (26.5–103.7; n = 19) in cohort 2, respectively
(Figure 2). Across all weight groups in cohort 1 and over-
all in cohort 2, the median Cminss values were consistent
and above the target therapeutic exposure of 10 lg/ml.
After the effect of body weight was taken into account,
there was no independent age effect on Cminss (see Supple-
mentary Materials, available at http://onlinelibrary.wiley.
com/doi/10.1002/art.40466/abstract). The results of this
study do not indicate that Cminss values >10 lg/ml were
associated with either greater effectiveness or an increase
in rates of AEs (including infections) at the month 4 time
point (data not shown).
Enrolled
N = 234
Entered 20-month
extension period
(part 2)
n = 43 (93.5%)*
Completed 20-month
extension period
(part 2)
n = 24 (52.2%)
Completed initial
4-month period
(part 1)
n = 43 (93.5%)
Entered initial
4-month period
(part 1)
n = 46
Entered 20-month
extension period
(part 2)
n = 157 (90.8%)
Completed 20-month
extension period
(part 2)
n = 132 (76.3%)
Completed initial
4-month period
(part 1)
n = 162 (93.6%)
Entered initial
4-month period
(part 1)
n = 173
Screening failures
n = 14
Discontinued
AEs
Lack of efficacy
Withdrawal of consent
Poor/noncompliance
n = 11 (6.4%)
n = 3
n = 5
n = 2
n = 1
Discontinued
AEs
Lack of efficacy
Withdrawal of consent
No longer met study criteria
Pregnancy
n = 25 (14.5%)
n = 4
n = 12
n = 6
n = 2
n = 1
Screening failures
n = 1
Discontinued
Lack of efficacy
AEs
n = 4 (8.7%)
n = 3
n = 1
Discontinued
Lack of efficacy
Withdrawal of consent
n = 3 (6.5%)
n = 2
n = 1
Cohort 1 Cohort 2
Figure 1. Patient disposition. * = treatment ongoing at time of analysis in 15 patients (32.6%). AEs = adverse events.
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Effectiveness. In both cohorts, robust JIA-ACR
responses were observed as early as month 1 (Figures 3A
and B) (for “as observed” analysis, see Supplementary
Materials). At month 4, JIA-ACR 30 response rates were
83% and 89% in cohorts 1 (n = 173) and 2 (n = 46),
respectively. JIA-ACR 30 response rates in cohorts 1 and
2, respectively, were 75% and 96% at month 21, and 58%
and 100% at month 24. Higher-level JIA-ACR response
rates increased steadily to month 21 (see Figures 3A and
B, and Supplementary Materials, available at http://online
library.wiley.com/doi/10.1002/art.40466/abstract). Inactive
disease status was achieved at month 4 by 30% and 50%
of patients in cohorts 1 and 2, respectively. JIA-ACR
responses were in line with JADAS-71–CRP scores, per
the “as-observed” analysis, reflecting low disease activity
in 42.8% and 90.9% of patients in cohorts 1 and 2,
Table 1. Summary of baseline demographics and clinical characteristics of the JIA patients*
Characteristic Cohort 1 (n = 173) Cohort 2 (n = 46)
Age, median (IQR) years 13.0 (10.0–15.0) 4.0 (3.0–5.0)
Female sex 136 (78.6) 28 (60.9)
Weight, median (IQR) kg 45.0 (31.5–57.0) 18.0 (15.0–21.1)
Weight category
<25 kg 18 (10.4) 43 (93.5)
25 to <50 kg 74 (42.8) 3 (6.5)
≥50 kg 81 (46.8) 0
Ethnicity
White 144 (83.2) 44 (95.7)
African American 14 (8.1) 1 (2.2)
Other 15 (8.7) 1 (2.2)
Disease duration, median (IQR) 2.0 (0.0–4.0) 0.5 (0.0–1.0)
<2 years 102 (59.0) 42 (91.3)
2 to <5 years 37 (21.4) 4 (8.7)
5 to ≤10 years 30 (17.3) 0
>10 years 4 (2.3) 0
JIA category
Polyarthritis RF negative 94 (54.3) 29 (63.0)
Polyarthritis RF positive 46 (26.6) 3 (6.5)
Extended oligoarthritis 19 (11.0) 10 (21.7)
Systemic arthritis 5 (2.9) 0
Psoriatic arthritis 0 4 (8.7)
Enthesitis-related arthritis 4 (2.3) 0
Undifferentiated or persistent oligoarthritis† 5 (2.9) 0
JIA-ACR core set variable, median (IQR)
No. of active joints 10.0 (6.0–19.0) 7.0 (6.0–12.0)
No. of joints with limitation of motion 8.0 (4.0–15.0) 8.0 (4.0–11.0)
Physician global assessment 48.0 (31.0–67.0) 50.0 (35.0–60.0)
Parent’s global assessment‡ 47.8 (24.1–68.0) 42.1 (17.9–54.7)
C-HAQ DI‡ 0.9 (0.4–1.5) 1.2 (0.8–1.6)
CRP, mg/dl§ 0.2 (0.1–0.9) 0.1 (0.1–1.4)
JADAS-71–CRP, median (IQR)¶ 21.0 (13.5–30.3) 18.1 (14.0–23.1)
MTX use at baseline 136 (78.6) 37 (80.4)
MTX dose at baseline, median (IQR) mg/m2/week 11.6 (9.7–14.4) 13.3 (10.9–15.3)
Route of MTX administration
Oral 76 (43.9) 18 (39.1)
Parenteral# 60 (34.7) 19 (41.3)
Oral corticosteroid use at baseline** 56 (32.4) 9 (19.6)
Oral prednisone (or equivalent) dose at baseline, median (IQR) mg/kg/day†† 0.1 (0.1–0.2) 0.2 (0.2–0.4)
Prior biologic use‡‡ 46 (26.6) 10 (21.7)
* Except where indicated otherwise, values are the number (%) of patients. Cohort 1 consisted of patients ages 6–17 years,
and cohort 2 consisted of patients ages 2–5 years. JIA = juvenile idiopathic arthritis; IQR = interquartile range; RF = rheuma-
toid factor; JIA-ACR = JIA–American College of Rheumatology criteria for improvement; C-HAQ DI = Childhood Health
Assessment Questionnaire disability index; JADAS-71–CRP = Juvenile Arthritis Disease Activity Score in 71 joints using the
C-reactive protein level; MTX = methotrexate.
† Protocol violation.
‡ In cohort 1, n = 172.
§ Normal ≤0.6 mg/dl.
¶ In cohort 1, n = 171.
# Includes subcutaneous and intramuscular administration.
** Prednisone or prednisolone.
†† In cohort 1, n = 52; in cohort 2, n = 8.
‡‡ Adalimumab, etanercept, or tocilizumab.
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respectively, at month 24. The median JADAS-71–CRP
values were below the cutoff value for low disease activity
in polyarthritis by month 7 in cohort 1 and by month 3 in
cohort 2; these values reached the lowest level of 1.3 at
month 24 in cohort 1, and of 0.5 at month 19 in cohort 2
(Figures 4A and B). In cohort 1, all 6 JIA-ACR core set
variables, including C-HAQ DI and parent’s global assess-
ment of patient overall well-being, improved over time
and these values were maintained until the end of the
study (see Supplementary Materials, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wi
ley.com/doi/10.1002/art.40466/abstract). Additional results
of JIA category analyses (cohort 1) can also be found in
the Supplementary Materials.
Safety and immunogenicity. In total, 309.8 and
71.0 patient-years of follow-up were available from the
safety populations in cohorts 1 and 2, respectively. As
shown in Table 2, abatacept was well tolerated in both
cohorts throughout the study. AEs occurred in 152
patients (87.9%) in cohort 1 and in 43 patients (93.5%)
in cohort 2. SAEs occurred in 14 patients (8.1%) in
cohort 1 and 3 (6.5%) in cohort 2. In cohort 1, the inci-
dence rates of AEs and SAEs per 100 patient-years of
exposure were 173.0 (95% CI 147.6–202.8) and 4.7
(95% CI 2.8–7.9), respectively. Two SAEs were consid-
ered related to the study drug: sepsis (n = 1; severe
intensity) in cohort 1 and overdose (n = 1; mild inten-
sity) in cohort 2, in a patient in whom a higher abata-
cept dose was administered due to misclassification of
weight tier. One malignancy, stage III ovarian germ cell
teratoma (severe intensity) was reported in cohort 1 on
study day 99, but was considered by the investigator to
0
10
20
50 mg 
(n = 14) 
87.5 mg 
(n = 62) 
Weight-tiered dose
125 mg 
(n = 59)
C
m
in
ss
 (µ
g
/m
l)
0
10
20
40
60
80
100
120
140
50 mg 
(n = 7) 
87.5 mg 
(n = 35) 
Weight-tiered dose
125 mg 
(n = 37)
C
m
in
ss
 (µ
g
/m
l)
40
60
80
100
120
140
Month 4 
(n = 30) 
Time
Month 24
(n = 19)
C
m
in
ss
 (µ
g
/m
l)
0
10
20
40
60
80
100
120
140
A
B
Figure 2. Abatacept steady-state trough concentration (Cminss) in patients ages 6–17 years (cohort 1) by weight group (A) at month 4 (left) and
month 24 (right), and patients ages 2–5 years (cohort 2) at months 4 and 24 (B). Cminss was summarized for treated patients (≥1 dose of study
medication) with evaluable pharmacokinetic measurements at each time point. Data are shown as box plots. Each symbol represents a single sub-
ject. Boxes represent the upper and lower interquartile range. Lines inside the boxes represent the median. Whiskers represent the 5th and 95th
percentiles. Dashed lines indicate the target therapeutic concentration.
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be unrelated to the study drug. Three autoimmune dis-
orders (none of which were considered related to the
study drug) were reported in cohort 1: pediatric autoim-
mune neuropsychiatric disorder associated with strepto-
coccal infection (mild intensity) on study day 71,
psoriasis (mild intensity) on study day 327, and
Takayasu arteritis (moderate intensity) on study day
416. There were no reported cases of malignancies or
autoimmune disorders in cohort 2.
Local injection site reactions were of mild or mod-
erate intensity and occurred in 12 patients (6.9%) in
cohort 1 and 2 (4.3%) in cohort 2 (none of which led to
discontinuation). Seven local injection site reactions of
moderate intensity occurred in 3 patients in cohort 1, and
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Figure 3. Juvenile Idiopathic Arthritis–American College of Rheumatology (JIA-ACR) 30, 50, 70, 90 improvement criteria response rates over
time for patients ages 6–17 years (cohort 1; intent-to-treat [ITT] population analysis) (A) and patients ages 2–5 years (cohort 2; ITT population
analysis to month 4 [study part 1], “as-observed” population analysis thereafter to month 24 [study part 2]) (B). Bars show the 95% confidence
intervals. The apparent decrease in response rates at month 24 in cohort 1 reflects a decreased number of patients with available data at this time
point and the associated increased proportion of patients imputed as nonresponders due to missing values.
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1 patient required treatment. The overall rates of patients
with infections in cohorts 1 and 2, respectively, were
68.2% and 78.3%. All marked laboratory abnormalities
were mild or moderate, and no deaths occurred during the
study (for further details, see Supplementary Materials,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract).
Overall, 4 of 172 patients (2.3%) in cohort 1, and 4
of 46 (8.7%) in cohort 2 developed antibodies reactive with
abatacept while receiving treatment during the cumulative
period, but antibody positivity did not persist. The pres-
ence of these antibodies had no apparent effect on PK,
effectiveness, or safety (see Supplementary Materials,
available at http://onlinelibrary.wiley.com/doi/10.1002/art.
40466/abstract).
DISCUSSION
In this phase III study of weekly weight-tiered SC
abatacept in patients with polyarticular JIA, the primary
end point of abatacept Cminss at month 4 in patients ages
6–17 years was shown to be consistently above the
planned minimal target therapeutic exposure of Cminss 10
lg/ml, without compromising patient safety. The target
therapeutic exposure was achieved at month 4 across all
weight groups in cohort 1, and overall in cohort 2.
SC abatacept was effective and improved function and
patient well-being over the 24-month cumulative treat-
ment period in both cohorts, with a low rate of discontinu-
ation due to AEs.
The PK data confirm the feasibility of a weekly
weight-tiered SC abatacept treatment regimen for
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Figure 4. Baseline and post-baseline Juvenile Arthritis Disease Activity
Score in 71 joints using the C-reactive protein level (JADAS-71–CRP) in
cohort 1 (A) and cohort 2 (B). Values are the median and interquartile
range. JADAS-71–CRP variables included number of active joints, physi-
cian’s global assessment of disease activity, parent’s global assessment of
patient well-being, and laboratory measurement of inflammation, as
measured by CRP. Dashed lines show the JADAS-71–CRP cutoff values
for inactive disease, low disease activity, and high disease activity (1, 3.8,
and 10.5, respectively) (33,35).
Table 2. Adverse events over the 24-month cumulative period (all
treated patients)*
Event
Cohort 1
(n = 173)
Cohort 2
(n = 46)
Exposure, patient-years 309.8 71.0
Deaths 0 0
SAEs† 14 (8.1) 3 (6.5)
Treatment-related SAEs‡ 1 (0.6) 1 (2.2)
Discontinuations due to SAEs 4 (2.3)§ 0
Incidence rate, per 100 patient-years 4.68 4.41
AEs (including SAEs) 152 (87.9) 43 (93.5)
Treatment-related AEs 54 (31.2) 27 (58.7)
Discontinuations due to AEs¶ 7 (4.0) 1 (2.2)
Incidence rate, per 100 patient-years 173.03 426.44
AEs of special interest#
Malignancies 1 (0.6) 0
Autoimmune disorders 3 (1.7) 0
Local injection-site reactions/pain 12 (6.9) 2 (4.3)
Infections 118 (68.2) 36 (78.3)
* Except where indicated otherwise, values are the number (%) of
patients.
† In cohort 1, serious adverse events (SAEs) included sepsis, abdomi-
nal pain, and upper respiratory tract infection (all 3 of which
occurred in 1 patient), hypomagnesemia and stage III ovarian germ
cell teratoma (both occurred in 1 patient), appendicitis, pneumonia,
pyelonephritis, concussion, radius fracture, urinary calculus, nephro-
lithiasis, anemia, vertigo, chest pain, synovitis, and autonomic nervous
system imbalance; in cohort 2, SAEs included overdose, tendon disor-
der, and febrile convulsion (each in 1 patient).
‡ Treatment-related SAEs included sepsis of severe intensity in cohort 1
and an overdose of mild intensity (administration of a higher abatacept
dose due to misclassification by weight tier) in cohort 2.
§ Includes discontinuations due to the following SAEs: sepsis, vertigo,
stage III ovarian germ cell teratoma, and autonomic nervous system
imbalance.
¶ Discontinuations due to sepsis, vertigo, stage III ovarian germ cell
teratoma, autonomic nervous system imbalance, exanthema, fatigue,
and aphthous ulcer in cohort 1; and pyrexia, rhinitis, and cough (all
in 1 patient) in cohort 2.
# No opportunistic infections (including extrapulmonary tuberculosis
and herpes zoster) related to study drug occurred in either cohort
during the study. In cohort 1, stage III ovarian germ cell teratoma
was the only malignancy; autoimmune disorders included pediatric
autoimmune neuropsychiatric disorders associated with streptococcal
infections, psoriasis, and Takayasu arteritis.
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polyarticular JIA in patients ages 2–17 years old (see
Supplementary Materials, http://onlinelibrary.wiley.com/
doi/10.1002/art.40466/abstract). The observed Cminss
values were within the ranges of exposure previously
found for IV abatacept (10 mg/kg) in patients with
JIA (23) and in adults with RA receiving IV or SC
abatacept treatment (36) (also see Supplementary
Materials). Abatacept Cminss values at months 4 and
24 were comparable, demonstrating that the target
therapeutic exposure is maintained with continued
treatment.
The robust JIA-ACR response rates and improve-
ments in JADAS-71–CRP scores to month 24 demon-
strated in our study support the use of weekly weight-tiered
SC abatacept therapy in patients with polyarticular JIA.
In both cohorts, an early onset of treatment response was
observed, with responses maintained throughout the
study. In cohort 1, analysis of the 6 JIA-ACR core
variables revealed a beneficial effect of SC abatacept on
function (C-HAQ DI) and well-being (parent’s global
assessment of patient overall well-being).
SC abatacept was well tolerated in both cohorts,
with no new safety concerns observed. Safety and immuno-
genicity profiles were similar in cohorts 1 and 2. Although
the rate of infections was higher than that observed in a
study of adult patients with RA who were treated with aba-
tacept (16), this finding was somewhat expected due to a
known greater susceptibility of children to infections as
compared with adults. Notably, there were no reported
opportunistic infections related to abatacept treatment in
patients with polyarticular JIA, even in countries with a high
burden of tuberculosis, which is consistent with observations
in adults with RA who receive abatacept treatment (37). In
addition, there were no malignancies or autoimmune disor-
ders in cohort 2, and the rate of these events was minimal
in cohort 1. The safety of SC abatacept was largely consis-
tent with that of IVabatacept in polyarticular JIA (2,9,13).
Tolerability of SC injections is of special concern
in pediatric patients. In this study, SC abatacept treat-
ment yielded an overall low rate of local injection site
reactions, most of which were mild—only a few moder-
ate and no severe reactions were reported. Notably, no
local injection site reactions led to treatment discontinu-
ation. Fewer patients developed anti-abatacept antibod-
ies while receiving SC abatacept treatment compared
with IV abatacept treatment (2); this was somewhat
expected given that similar trends were observed in a
study of adult patients with RA who received SC or IV
abatacept plus MTX and had inadequate responses to
MTX (22). This finding was also possibly related to the
concomitant use of MTX in ≥75% of patients in the
current study and differences in study designs.
The effectiveness of SC abatacept treatment
demonstrated in the current study constitutes a conserva-
tive interpretation of the data. Despite the observational
character of the study, an ITTanalysis was performed for
the cumulative period in cohort 1 and up to month 4 in
cohort 2, in which patients discontinuing the study prior
to month 24 or not having data available at this time point
were imputed as nonresponders.
Abatacept is seldom used to treat polyarticular
JIA early in the disease course. The results from cohort 2
in this study, in which abatacept treatment was initiated in
patients with a median disease duration of only 0.5 years,
provide valuable data regarding the early introduction of
abatacept therapy; notably, JIA-ACR response rates were
consistently higher in cohort 2 than in cohort 1.
The study has some limitations, including the
open-label design and a protocol violation, in which a few
patients with undifferentiated and persistent oligoarthritis
entered the trial despite not meeting the eligibility criter-
ia. Additionally, the use of concomitant medications such
as MTX and corticosteroids, as well as prior use of bio-
logic DMARDs (including TNFi) in some patients, may
have had confounding effects. However, the sample sizes
of the corresponding subgroups were too small to analyze.
In conclusion, weight-tiered weekly SC abatacept
was effective in patients with polyarticular JIA, with no
new safety concerns identified. These data suggest that
SC abatacept provides an effective and well-tolerated
treatment option for patients with polyarticular JIA, with
the additional benefit of the convenience associated with
self or parent/caregiver administration of the treatment.
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